We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

AZJ:ASXAurizon Holdings Ltd. Analysis

Data as of 2026-06-18 - not real-time

A$4.21

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Aurizon (AZJ) is trading at AUD 4.21, just above the 20‑day SMA (4.255) and comfortably above the 50‑day SMA (4.184), indicating a short‑term bullish bias despite a bearish MACD histogram and a neutral RSI of 46.6. The stock sits near its technical support at 4.12 and faces resistance around 4.42, while volume is on an upward trend, suggesting buying pressure may be building. Valuation metrics show a trailing PE of 23.4 versus an industry average of 31.2, but the forward PE of 14.9 and a target mean price of 3.87 imply the market is pricing in expectations above the consensus forecast. The balance sheet is heavily leveraged with a debt‑to‑equity ratio of 136.9 and cash covering less than 3% of total debt, raising concerns about financial flexibility. Operating margins are solid at 24.9% and gross margin at 42.1%, yet revenue growth is modest at 2.1% and ROE is only 7.2%, limiting growth upside. Overall, the stock presents a mixed picture: technical strength and relative valuation appeal are offset by high leverage and limited dividend yield, positioning AZJ as a borderline fair‑value play with medium‑term hold potential.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price hovering above technical support (4.12) with increasing volume
  • Bullish SMA alignment (20‑day > 50‑day > 200‑day)
  • Relative PE advantage over industry peers

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • High debt‑to‑equity ratio limiting financial flexibility
  • Modest revenue growth (2.1%) and low ROE
  • Forward PE compression suggesting limited upside

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Stable demand for rail freight in mining and agriculture sectors
  • Potential for deleveraging through asset sales or cash flow generation
  • Absence of dividend requiring reliance on capital appreciation

Key Metrics & Analysis

Financial Health

Revenue Growth2.10%
Profit Margin7.63%
P/E Ratio23.4
ROE7.23%
ROA4.71%
Debt/Equity136.85
P/B Ratio1.7
Op. Cash FlowA$1.5B
Free Cash FlowA$357.2M
Industry P/E31.2

Technical Analysis

TrendBullish
RSI46.7
SupportA$4.12
ResistanceA$4.42
MA 20A$4.26
MA 50A$4.18
MA 200A$3.74
MACDBearish
VolumeIncreasing
Fear & Greed Index88.5

Valuation

Target PriceA$3.87
Upside/Downside-8.02%
GradeFair
TypeBlend

Risk Assessment

Beta0.29
Volatility18.30%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.